[HTML] elifesciences.org

[HTML][HTML] Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

SM Rothenberg, K Concannon, S Cullen, G Boulay… - Elife, 2015 - elifesciences.org
Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor regression
but it is invariably followed by drug resistance. In characterizing early transcriptional …
被引用次数：47 相关文章

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

SM Rothenberg, K Concannon, S Cullen, G Boulay… - eLife, 2015 - cir.nii.ac.jp
抄録< jats: p> Treatment of< jats: italic> EGFR</jats: italic>-mutant lung cancer with erlotinib
results in dramatic tumor regression but it is invariably followed by drug resistance. In …
[PDF] academia.edu

[PDF][PDF] Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

SM Rothenberg, K Concannon, S Cullen, G Boulay… - academia.edu
Abstract Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor
regression but it is invariably followed by drug resistance. In characterizing early …
[PDF] elifesciences.org

[PDF][PDF] Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

SM Rothenberg, K Concannon, S Cullen, G Boulay… - cdn.elifesciences.org
Abstract Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor
regression but it is invariably followed by drug resistance. In characterizing early …

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways.

SM Rothenberg, K Concannon, S Cullen, G Boulay… - Elife, 2015 - europepmc.org
Abstract Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor
regression but it is invariably followed by drug resistance. In characterizing early …
[HTML] elifesciences.org

[HTML][HTML] Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

SM Rothenberg, K Concannon, S Cullen, G Boulay… - eLife, 2015 - elifesciences.org
Abstract Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor
regression but it is invariably followed by drug resistance. In characterizing early …

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

RS Michael, K Concannon, S Cullen, B Gaylor… - eLife, 2015 - search.proquest.com
Abstract Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor
regression but it is invariably followed by drug resistance. In characterizing early …

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

SM Rothenberg, K Concannon, S Cullen, G Boulay… - 2015 - agris.fao.org
Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor regression
but it is invariably followed by drug resistance. In characterizing early transcriptional …
[PDF] psu.edu

[PDF][PDF] Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

SM Rothenberg, K Concannon, S Cullen, G Boulay… - 2015 - Citeseer
Abstract Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor
regression but it is invariably followed by drug resistance. In characterizing early …

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

SM Rothenberg, K Concannon, S Cullen, G Boulay… - …, 2015 - pubmed.ncbi.nlm.nih.gov
Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor regression
but it is invariably followed by drug resistance. In characterizing early transcriptional …